Telomir Pharmaceuticals (TELO) Expected to Post Quarterly Earnings on Wednesday

Telomir Pharmaceuticals (NASDAQ:TELO) is projected to release its results after the market closes on Wednesday, September 2nd. Analysts expect Telomir Pharmaceuticals to post earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.72).

Telomir Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ:TELO opened at $1.12 on Tuesday. The business has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.25. Telomir Pharmaceuticals has a twelve month low of $0.89 and a twelve month high of $2.09. The company has a market cap of $77.03 million, a price-to-earnings ratio of -1.23 and a beta of -0.24.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in shares of Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after purchasing an additional 10,880 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in Telomir Pharmaceuticals in the second quarter worth $33,000. Geode Capital Management LLC boosted its stake in Telomir Pharmaceuticals by 14.0% during the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock worth $297,000 after buying an additional 27,519 shares in the last quarter. XTX Topco Ltd bought a new stake in Telomir Pharmaceuticals in the 4th quarter valued at $53,000. Finally, Jane Street Group LLC acquired a new position in shares of Telomir Pharmaceuticals in the 2nd quarter valued at $62,000.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.